Pay in 4 interest-free payments of $6.95 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Viking Therapeutics (VKTX): The pure-play GLP-1 development company reported promising Phase 2 data for its own obesity candidate, VK2735
The FDA has received adverse event reports, some requiring hospitalization, involving dosing errors in which patients administered five to twenty times their intended dose, due to unfamiliarity with vial-to-syringe measurement and confusion between units
Particularly, NASH and CKD are areas where successful drug development has been challenging, and a new effective treatment could be a significant revenue driver
Endometriosis: Treatment of infertility in females
US$ 24.22
US$ 27.93
US$ 20.12
US$ 26.20
US$ 23.05
